<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139434">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755182</url>
  </required_header>
  <id_info>
    <org_study_id>LOTUS</org_study_id>
    <secondary_id>2011-006097-76</secondary_id>
    <nct_id>NCT01755182</nct_id>
  </id_info>
  <brief_title>Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors</brief_title>
  <acronym>LOTUS</acronym>
  <official_title>Randomized Phase 3 Trial Evaluating the Efficacy of Locoregional Treatment With Transarterial Embolization (TAE) for Liver Metastases, in Combination With Octreotide LAR, in Patients With Neuroendocrine Tumor and Inoperable Liver Metastasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second University of Naples</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify if adding a locoregional treatment of liver
      metastasis (with trans-arterial embolization-TAE) to a medical treatment (with Octreotide
      LAR and eventually in combination with other medical treatments of proven efficacy), can
      prolong the progression free survival of patients affected by neuroendocrine tumors (NET)
      with inoperable liver metastases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NET patients with unresectable hepatic metastases at diagnosis or who have not received any
      antineoplastic therapy for metastatic disease will be registered in the study and sent to a
      screening phase. Randomization will be proposed to patients with progressive  hepatic or
      symptomatic disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of objective responses</measure>
    <time_frame>measured at 3 months and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade adverse event per patient</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>exploratory analysis of prognostic factors</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical factors will be explored in relation to patient outcomes</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Pharmacologic therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAE and pharmacologic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide LAR</intervention_name>
    <description>30 mg IM every 28 days (the addition of other pharmacologic therapies of proven efficacy in NET is permitted)</description>
    <arm_group_label>Pharmacologic therapy</arm_group_label>
    <arm_group_label>TAE and pharmacologic therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAE</intervention_name>
    <description>after randomization, and after 3 months</description>
    <arm_group_label>TAE and pharmacologic therapy</arm_group_label>
    <other_name>transarterial embolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        At registration

          -  Diagnosis of  NET of gastroenteropancreatic (GEP), pulmonary or unknown primary site
             origin

          -  Unresectable liver metastases, according  the judgment of surgeon, (the reasons for
             the opinion of surgeon should be made explicit)

          -  Hepatic involvement  ≤50% volume of the organ

          -  Well (G1) or medium (G2) differentiated histology (according to WHO 2010
             classification)

          -  Ki67 ≤ 20% (G1-G2)

          -  Life expectancy &gt; 6 months

          -  Age ≥ 18 and &lt; 80 years

        At  randomization

          -  Confirmed criteria as per registration

          -  Radiological progression of hepatic localizations, verified during screening phase,
             or presence of symptoms requiring an immediate treatment with somatostatin analogues
             (I.E. in case of a functioning tumour, that doesn't need of a symptomatic therapy
             with analogues of somatostatin [insulinoma, gastrinoma, ACTHoma], it is necessary to
             wait for radiological progression)

        Exclusion Criteria:

        At registration

          -  Previous loco-regional postsurgical treatment

          -  Low differentiated histology

          -  Severe concomitant morbidities such as: severe coagulopathy, severe liver failure (to
             be detailed), renal failure (creatinine &gt; 2.0 mg/dl) and heart failure (NYHA 3-4 or
             instable ischemic heart disease),  contraindicating the interventional procedure or
             influencing the general prognosis (Investigator to provide details of exclusion)

          -  Extrahepatic metastasis in critical locations as: brain, spinal cord, lung with
             respiratory impairment, symptomatic vertebral lesions

        At randomization

          -  Patients with progression of disease only on the extra-hepatic localizations during
             screening phase

          -  Patients with progression disease  on critical location such as: brain, spinal cord,
             lung with respiratory impairment, symptomatic vertebral lesions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A Colao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Faggiano, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R D'Angelo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F Fiore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F Perrone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C Gallo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second University of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MC Piccirillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <phone>+39 081 5903571</phone>
    <email>francesco.perrone@usc-intnapoli.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marilina Piccirillo, M.D.</last_name>
    <phone>+39 081 5903383</phone>
    <email>marilina.piccirillo@usc-intnapoli.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Albano Laziale Ospedale &quot;Regina Apoltolorum&quot;</name>
      <address>
        <city>Albano Laziale</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>MIlano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria S.M. della Misericordia di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università di Verona Policlinico GB Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locoregional treatment</keyword>
  <keyword>liver metastases</keyword>
  <keyword>transarterial embolization</keyword>
  <keyword>upfront treatment</keyword>
  <keyword>inoperable</keyword>
  <keyword>octreotide</keyword>
  <keyword>gastroenteropancreatic (GEP)primary</keyword>
  <keyword>pulmonary primary</keyword>
  <keyword>primary unknown origin</keyword>
  <keyword>systemic therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
